Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

@article{Armand2007ImpactOC,
  title={Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.},
  author={Philippe F Armand and Haesook T Kim and Daniel J. Deangelo and Vincent Trien-Vinh Ho and Corey S Cutler and Richard M Stone and Jerome Ritz and Edwin P Alyea and Joseph H Antin and Robert J. Soiffer},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2007},
  volume={13 6},
  pages={655-64}
}
Cytogenetics has an important impact on the prognosis of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). However, it is unclear whether currently accepted cytogenetic risk groups, which were established for patients treated mostly with standard therapy, are optimally discriminating for patients undergoing HSCT. Also, the impact of cytogenetics in the growing population of patients with therapy… CONTINUE READING